Drugmaker AstraZeneca invests big in the U.S.
Marketplace Morning Report
00:00
AstraZeneca's $50 Billion Bet on U.S. Manufacturing
This chapter explores AstraZeneca's historic $50 billion investment in U.S. manufacturing by 2030, signaling a strategic pivot in response to potential tariffs. The discussion delves into the implications for both the UK and US pharmaceutical landscapes.
Transcript
Play full episode
